Aurinia Pharmaceuticals price target raised to $15 from $14 at H.C. Wainwright

H.C. Wainwright analyst Ed Arce raised the firm’s price target on Aurinia Pharmaceuticals to $15 from $14 and keeps a Buy rating on the shares post the Q2 report. The analyst says the commercialization of Lupkynis continues to gain traction. Aurinia’s newer commercial strategies implemented over the last 12 months, combined with a near-normal, post-pandemic environment in the medical community, are gaining significant traction in both the nephrology and rheumatology marketplaces, the analyst tells investors in a research note.